Citi Taps Insilico as Its Top Pick in China's Healthcare Sector

Citi Research identifies AI-powered drug discovery as the next major growth opportunity in China's healthcare industry, naming Insilico as its top pick.

The investment bank notes that AI-driven drug discovery is rapidly gaining momentum in China, drawing substantial investor interest because artificial intelligence provides significant speed and cost benefits to pharmaceutical development.

Citi notes that vendors offering AI-based wet-lab validation currently represent the most attractive near-term investment opportunities in China's healthcare sector.

For the longer term, however, the bank favors AI-native drug developers such as Insilico, believing their proprietary AI-driven discovery platforms can evolve into superior, differentiated clinical assets that generate exponential value.

Citi rates Insilico a Buy with a price target of HK$85, describing the firm as a hybrid platform and pipeline company whose current valuation is anchored to its clinical-stage assets.

Long-term upside, according to Citi, depends on Insilico's ability to repeatedly translate its AI capabilities into novel clinical assets.

Citi also points to the recent identification of drug targets Z and Y—detailed in company press releases—as breakthrough achievements.

Moreover, Insilico's small-molecule candidate Rentosertib has completed the validation chain from target to Phase III, demonstrating the company's capacity for consistent AI-enabled drug creation.

Such a track record underpins Citi's constructive outlook and supports its selection of the stock as the top pick in China's healthcare sector.

This article was prepared with AI assistance and reviewed by an editor. For further information, please refer to our Terms and Conditions.